Abstract: Aspects of the present invention relate to compositions of bacterial isolates with probiotic activity. Aspects of the present invention also relate to compositions and methods that may confer health benefits to subjects in need thereof. This may be accomplished by administering to the subject an effective amount of the microorganism isolates and may include also administering an effective amount of a prebiotic, stabilizer, antibacterial agent, antifungal agent, and/or media component. Probiotic compositions may also be in combination with a suitable delivery system, such as a food product or a beverage, a food or beverage compositions, a food or beverage supplement or adjuvant.
Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
Type:
Grant
Filed:
June 2, 2022
Date of Patent:
April 23, 2024
Assignees:
The University of Chicago, J. Craig Venter Institute, Inc., The University of Sheffield, Institute for Systems Biology, The University of Leeds, The University of Strathclyde, The Government of the United States
Inventors:
Rima McLeod, Martin McPhillie, Colin W. G. Fishwick, Hernan Alejandro Lorenzi, Kai Wang, Taek-Kyun Kim, Yong Zhou, Leroy E. Hood, Ying Zhou, Kamal El Bissati, Mark Hickman, QiGui Li, Craig Roberts
Abstract: Provided herein are compositions comprising a resolvin mimetic. Such mimetics may comprise an anti-ERV1 antibody, such as a resolvimab, or biologically-active antibody fragment thereof. Also provided herein are methods for treating or preventing an inflammatory disorder in a subject in need thereof comprising the steps of administering a therapeutically effective amount of at least one resolvin mimetic.
Abstract: Described herein are engineered microalgae that exhibit enhanced lipid production during exponential growth. Such engineered microalgae are useful, for example, for the production of biofuels.
Abstract: Provided herein are compositions comprising a resolvin mimetic. Such mimetics may comprise an anti-ERV1 antibody, such as a resolvimab, or biologically-active antibody fragment thereof. Also provided herein are methods for treating or preventing an inflammatory disorder in a subject in need thereof comprising the steps of administering a therapeutically effective amount of at least one resolvin mimetic.
Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
October 1, 2019
Assignees:
Novartis AG, J. Craig Venter Institute, Inc.
Inventors:
John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
Abstract: Vaccine compositions useful for vaccination against a target influenza strain, and method and kits for using the same. The vaccines comprise a live attenuated influenza virus that is synthetically constructed based upon a backbone platform derived from a bat influenza strain, and heterologous surface proteins HA and NA derived from the target influenza strain. The live attenuated virus is non-reassortant with native, circulating influenza strains, and can be used to create vaccines for humans and other animals.
Type:
Grant
Filed:
September 4, 2015
Date of Patent:
April 30, 2019
Assignees:
KANSAS STATE UNIVERSITY RESEARCH FOUNDATION, J. CRAIG VENTER INSTITUTE
Inventors:
David Wentworth, Bin Zhou, Wenjun Ma, Jingjiao Ma
Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
Type:
Application
Filed:
June 26, 2018
Publication date:
October 18, 2018
Applicants:
GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
Inventors:
Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
Abstract: Described herein are engineered microalgae that exhibit enhanced lipid production during exponential growth. Such engineered microalgae are useful, for example, for the production of biofuels.
Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
Type:
Grant
Filed:
June 26, 2015
Date of Patent:
December 12, 2017
Assignees:
Novartis AG, J. Craig Venter Institute, Inc.
Inventors:
John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
Abstract: Bacteriophages are provided that infect strains of Enterococcus faecalis, an opportunistic bacterial pathogen that causes human disease. Also provided are methods of treating Enterococcus faecalis by therapeutic administration of such bacteriophages.
Type:
Grant
Filed:
March 25, 2014
Date of Patent:
October 24, 2017
Assignees:
TEMPLE UNIVERSITY—Of The Commonwealth System of Higher Education, J. Craig Venter Institute, Inc.
Inventors:
Roy H. Stevens, Hongming Zhang, Derrick E. Fouts, Jessica DePew
Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
Type:
Grant
Filed:
May 26, 2016
Date of Patent:
August 22, 2017
Assignees:
Novartis AG, J. Craig Venter Institute, Inc.
Inventors:
John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
Type:
Application
Filed:
May 9, 2016
Publication date:
August 25, 2016
Applicants:
GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
Inventors:
Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
Abstract: Polypeptides comprising various amino acid sequences derived from Haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis. They may also be useful for diagnostic purposes, and as targets for antibiotics. Antibodies against the polypeptides are also disclosed, as are the coding nucleic acids.
Type:
Application
Filed:
October 6, 2015
Publication date:
January 28, 2016
Applicants:
GLAXOSMITHKLINE BIOLOGICALS SA, J. CRAIG VENTER INSTITUTE, INC.
Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
Type:
Application
Filed:
June 2, 2014
Publication date:
December 4, 2014
Applicants:
J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRL
Inventors:
Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
Abstract: Described herein are methods for analyzing complex host-microbial mixtures. The disclosed methods may be used to diagnosis or prognose in a subject an inflammatory disease, which is caused by or contributed to by microbes.
Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
Type:
Grant
Filed:
February 17, 2006
Date of Patent:
June 24, 2014
Assignees:
Novartis Vaccines and Diagnostics Srl, J. Craig Venter Institute
Inventors:
Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
Abstract: Described herein are engineered microalgae that exhibit enhanced lipid production during exponential growth. Such engineered microalgae are useful, for example, for the production of biofuels.
Abstract: Featured herein are oxygen reduction electrodes configured in an electrochemical system, such as a microbial fuel cell, comprising a cathode configured as a pleated sheet and an anode comprised of a conductive material.